Maite Gorostegui/LinkedIn
May 5, 2024, 14:01
Maite Gorostegui: Our paper about Management of High-Risk Neuroblastoma in the Era of Anti-GD2 Immunotherapy
Maite Gorostegui, Pediatric Oncologist at Pediatric Cancer Center Barcelona, shared a post on LinkedIn:
“We just published our paper about Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
These heterogeneous group of patients with locoregional disease are at risk to be over/undertreated. To determine biology is fundamental for their prognosis. We report on patients with high risk biology and the positive impact of immunotherapy on these selected group of patients.
Hospital Sant Joan de Déu Barcelona
Jaume Mora, Cinzia Lavarino, Noelia Salvador, Lucas Krauel,Alicia Castañeda, Moira Garraus Oneca Cristina L., Juan Pablo Muñoz, Sara Perez-Jaume, Margarida Simao-Rafael, Salvador Mañe.”
Alicia Castañeda
Anti-GD2 Immunotherapy
cancer
Cinzia Lavarino
High-Risk Neuroblastoma
immunotherapy
Jaume Mora
Juan Pablo Muñoz
Lucas Krauel
Maite Gorostegui
Margarida Simao-Rafael
Moira Garraus Oneca Cristina L.
Noelia Salvador
OncoDaily
Oncology
Pediatric Cancer Center Barcelona
Salvador Mañe
Sara Perez-Jaume
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 1, 2024, 19:12
Nov 1, 2024, 17:46
Nov 1, 2024, 17:41
Nov 1, 2024, 17:27